Risedronate Sodium
NDC 0115-1426
Product Information
Risedronate Sodium is a ANDA-approved product labeled by Impax Generics. Risedronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. It is supplied as a orange product. This product entry covers the primary NDC 0115-1426 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
AG
Code Structure Chart
Product Details
What is NDC 0115-1426?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- RISEDRONATE SODIUM HEMI-PENTAHYDRATE (UNII: HU2YAQ274O)
- RISEDRONIC ACID (UNII: KM2Z91756Z) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- EDETATE DISODIUM (UNII: 7FLD91C86K)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)
- TRIETHYL CITRATE (UNII: 8Z96QXD6UM)
- TALC (UNII: 7SEV7J4R1U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1020064 - risedronate sodium 35 MG Delayed Release Oral Tablet
* Please review the full disclaimer at the bottom of this page.